These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 10652419)

  • 61. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease.
    Welters MJ; van der Logt P; van den Eeden SJ; Kwappenberg KM; Drijfhout JW; Fleuren GJ; Kenter GG; Melief CJ; van der Burg SH; Offringa R
    Int J Cancer; 2006 Feb; 118(4):950-6. PubMed ID: 16152582
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Identification of seroreactive epitopes of human papillomavirus type 18 E7 protein by synthetic peptides.
    Krchnák V; Pistĕk T; Vágner J; Suchánková A; Kañka J; Ritterová L; Vonka V
    Acta Virol; 1993 Oct; 37(5):395-402. PubMed ID: 7514354
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antibody response for L1, E6 and E7 HPV 16 and HPV 18 antigens in Tunisian women with cervical cancer and controls.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maalej M; Oueslati R
    J Immunoassay Immunochem; 2008; 29(3):266-80. PubMed ID: 18569375
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
    Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
    Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Occurrence of antibodies to L1, L2, E4 and E7 gene products of human papillomavirus types 6b, 16 and 18 among cervical cancer patients and controls.
    Köchel HG; Monazahian M; Sievert K; Höhne M; Thomssen C; Teichmann A; Arendt P; Thomssen R
    Int J Cancer; 1991 Jul; 48(5):682-8. PubMed ID: 1649138
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
    Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
    Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.
    Mbuya W; Held K; Mcharo RD; Haule A; Mhizde J; Mnkai J; Mahenge A; Mwakatima M; Sembo M; Mwalongo W; Agrea P; Hoelscher M; Maboko L; Saathoff E; Geisenberger O; Rwegoshora F; Torres L; Koup RA; Kroidl A; Chachage M; Geldmacher C
    Front Immunol; 2021; 12():742861. PubMed ID: 34759925
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16.
    Hasan UA; Bates E; Takeshita F; Biliato A; Accardi R; Bouvard V; Mansour M; Vincent I; Gissmann L; Iftner T; Sideri M; Stubenrauch F; Tommasino M
    J Immunol; 2007 Mar; 178(5):3186-97. PubMed ID: 17312167
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer.
    Smith EM; Pawlita M; Rubenstein LM; Haugen TH; Hamsikova E; Turek LP
    Int J Cancer; 2010 Jul; 127(1):111-7. PubMed ID: 19876924
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma.
    Ressler S; Scheiden R; Dreier K; Laich A; Müller-Holzner E; Pircher H; Morandell D; Stein I; Viertler HP; Santer FR; Widschwendter A; Even J; Jansen-Dürr P; Capesius C; Zwerschke W
    Clin Cancer Res; 2007 Dec; 13(23):7067-72. PubMed ID: 18056184
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
    Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16/18-positive cervical cancer cells.
    Ding W; Hu Z; Zhu D; Jiang X; Yu L; Wang X; Zhang C; Wang L; Ji T; Li K; He D; Xia X; Liu D; Zhou J; Ma D; Wang H
    Clin Cancer Res; 2014 Dec; 20(24):6495-503. PubMed ID: 25336692
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.
    Stiasny A; Kuhn C; Mayr D; Alexiou C; Janko C; Wiest I; Jeschke U; Kost B
    Anticancer Res; 2016 Jun; 36(6):3195-8. PubMed ID: 27272848
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.
    Viladiu P; Bosch FX; Castellsagué X; Muñoz N; Escribà JM; Hamsíkova E; Hofmannova V; Guerrero E; Izquierdo A; Navarro C; Moreo P; Izarzugaza I; Ascunce N; Gili M; Muñoz MT; Tafur L; Shah KV; Vonka V
    J Clin Oncol; 1997 Feb; 15(2):610-9. PubMed ID: 9053484
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antibodies to the E4, E6, and E7 proteins of human papillomavirus (HPV) type 16 in patients with HPV-associated diseases and in the normal population.
    Müller M; Viscidi RP; Ulken V; Bavinck JN; Hill PM; Fisher SG; Reid R; Munoz N; Schneider A; Shah KV
    J Invest Dermatol; 1995 Jan; 104(1):138-41. PubMed ID: 7798632
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Antibody response for L1, E6, E7 HPV 16, and HPV 18 antigens in Tunisian women with cervical cancer.
    Achour M; Zeghal D; Kochbati L; Kahla S; Zouari F; Maâlej M; Oueslati R
    J Immunoassay Immunochem; 2009; 30(1):82-96. PubMed ID: 19117204
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer.
    Combita AL; Bravo MM; Touzé A; Orozco O; Coursaget P
    Int J Cancer; 2002 Feb; 97(6):796-803. PubMed ID: 11857357
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Honeybee venom possesses anticancer and antiviral effects by differential inhibition of HPV E6 and E7 expression on cervical cancer cell line.
    Kim YW; Chaturvedi PK; Chun SN; Lee YG; Ahn WS
    Oncol Rep; 2015 Apr; 33(4):1675-82. PubMed ID: 25633640
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction.
    Iwasawa A; Nieminen P; Lehtinen M; Paavonen J
    Cancer; 1996 Jun; 77(11):2275-9. PubMed ID: 8635095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.